H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Translate Bio (NASDAQ:TBIO) Inc on Monday, setting a price target of $28, which is approximately 44.11% above the present share price of $19.43.
Fein expects Translate Bio Inc to post earnings per share (EPS) of -$0.27 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Translate Bio, with an average price target of $25.6.
The analysts price targets range from a high of $31 to a low of $20.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $51.39 million and a net profit of $7.85 million. The company's market cap is $1.46 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.3% and a 48.21% success rate.
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.